Pharmaceuticals Medicaid Medical Education Affordable Care Act Insurance Drug Pricing Public Health Regulations Medicare Reproductive Health Rural Health Pharmaceutical Pricing Public Health Initiatives Language Rights Mental Health Medical Access Research Funding Health Financing Universal Health Coverage Health Insurance Care Allowances Veterans Affairs NHS Hospital Administration Nursing Care Insurance Pharmaceutical Industry Public-Private Partnerships Elderly Care Cancer Care Labor Relations Commission Structure Abortion Access State Intervention Medical Equipment Prescription Drug Pricing Healthcare Initiatives Budget Cuts Regional Health Services Sick Leave Management Medical Ethics Administrative Reforms Nursing Care Social Insurance Emergency Services Vaccine Production Access to Medicines Long-Term Care Patient Rights Pharmaceutical Benefits Scheme Biosimilar Development Language Access Gender Identity Healthcare Financing Medical Debt Rural Healthcare Emergency Management Medication Distribution Ambulance Services Healthcare Administration Drug Advertising Nursing Homes Physiotherapy Pharmaceutical Advertising Medical Profession Public Trust Vaccine Access Gender Dysphoria Pharmaceutical Policy Long-term Care Funding and Resources Employee Benefits Healthcare Reform Vaccination Cancer Screening Health Systems Economic Assistance Benefits Drug Approval Funding Medical Cannabis Prescription Practices Biomedical Research Fertility Care Fertility Treatments Patient Support Procurement Medical Economics Pediatric Care Medical Education Policy Healthcare Staffing Pharmacy Regulations Pharmaceutical Regulations Regulatory Compliance Medical Division Civil Rights Medical Information Health Cards Prescription Drugs Welfare Reform Meeting Agenda
The agency forecasts more than $78 billion in federal savings with phased deadlines for states to unwind tax schemes.
